GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
Investor's Business Daily on MSN3h
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 BillionGSK stock rocketed Wednesday after the pharma titan raised its 2031 sales outlook to north of $50 billion.Please watch the ...
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates review designations in the pharmaceutical ...
Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback